Project description DEENESFRITPL DNA ‘photocopying’ technology expedites vaccine development The SARS-CoV-2 pandemic has highlighted the urgent need for the development of vaccines. To improve the efficiency and speed of vaccine design, the EU-funded BIOCOPY project has developed a patented technique that can significantly advance developmental processes at a lower cost. The technique utilises a DNA-coated surface to generate other biomolecules (DNA, RNA or proteins) which may serve as targets of pathogens and can be exploited for the development of vaccines. The high-throughput nature of the method ensures that hundreds of proteins are analysed at the same time, facilitating rapid turnover. Show the project objective Hide the project objective Objective "BioCopy is a spin-off company borned in the University of Freiburg. We have developed an innovative, patented technique to copy biomolecules analogous to a photocopier. A DNA-coated surface is used as copy template. By supplying different biochemical ""copy mixes"", either a DNA, a RNA or a protein copy is generated. After the copy process, the copied biomolecules can be analyzed label-free for their specific binding to target molecules and recovered as potential candidates for a future use as therapeutics or diagnostics. The BioCopy technology completely opens up new dimensions for drug development, vaccines, antibodies, enzymes, catalysts, bioactive coatings, and biosensors and it has are more than 40 future applications. We plan to offer 3 products and services to pharma and biotech companies, related with high- output and cheaper molecular biology screenings. The most promising line is the tailor-made discovery of vaccine candidates within two days. This will have a disruptive character, because the first generation of a vaccine is a billion-dollar market, projected to rise $60 billion on 2019, with 11% growth per annum, and to $100 billion by 2025. BioCopy will provide vaccine candidates to pharmaceuticals, obtaining revenues through upfront, milestone and royalty payments, and they will be responsible for the vaccine´s clinical development, approval and distribution. The multi-awarded BioCopy team covers business know-how and expertise in biology, physics, manufacturing systems engineering, assay development and microsystems technology. BioCopy aims to contribute to the European challenges related with advanced biotechnology applications in pharma sector, and to increase the technological transfer from the academic world into the manufacturing sector. During phase 1 we will build up a detailed business plan and a feasibility study, describing all the needed activities in order to reach BioCopy commercialization. We will need about €2.5M in phase 2." Fields of science medical and health sciencesbasic medicinepharmacology and pharmacydrug discoverynatural sciencesbiological sciencesgeneticsDNAmedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccinesnatural sciencesbiological sciencesgeneticsRNAnatural sciencesbiological sciencesmolecular biology Programme(s) H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs Main Programme H2020-EU.3. - PRIORITY 'Societal challenges H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies Topic(s) EIC-SMEInst-2018-2020 - SME instrument Call for proposal H2020-EIC-SMEInst-2018-2020 See other projects for this call Sub call H2020-SMEInst-2018-2020-1 Funding Scheme SME-1 - SME instrument phase 1 Coordinator BIOCOPY GMBH Net EU contribution € 50 000,00 Address ELZSTRASSE 27 79312 EMMENDINGEN Germany See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region Baden-Württemberg Freiburg Emmendingen Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 71 429,00
